Medetomidine is a potent alpha-2 agonist replacing xylazine in the unregulated opioid supply. It is a racemic mixture of dexmedetomidine and levomedetomidine — illicit samples contain both enantiomers in ~90% of cases. Withdrawal causes severe hypertension, tachycardia, and intractable vomiting — often

before opioid withdrawal appears. Early aggressive treatment with clonidine, opioids, and antiemetics may prevent ICU admission. Evidence is largely expert consensus and single-centre experience.

background

Medetomidine is a veterinary sedative pharmacologically similar to dexmedetomidine (Precedex). Increasingly found in unregulated fentanyl, with DEA forensic detections rising from 245 (2023) to 2,276 (2024).

Intoxication presents with profound sedation, sinus bradycardia (HR 30s–40s), and initial hypertension followed by hypotension.

Withdrawal starts within hours of last use (typically 4–6 hours) and can progress rapidly:

tachycardia, often > 120 bpm
hypertension, potentially severe (> 170/100)
severe nausea and vomiting — can quickly prevent PO medication use
sweating, anxiety, restlessness
waxing/waning alertness and mutism
tremor, myoclonic jerks
delirium or PRES in severe cases

Medetomidine withdrawal often begins

before opioid withdrawal. Suspect it when nausea/vomiting, hypertension, and tachycardia are out of proportion to typical opioid withdrawal.

Duration: mild–moderate 12–48 hours; severe ~3 days.

Associated findings: elevated lactate/metabolic acidosis, hypokalaemia, elevated troponins, QTc prolongation.

clinical presentations

ED with active withdrawal: combined features — opioid (diaphoresis, diarrhoea, myalgias, gooseflesh) + medetomidine (nausea/vomiting, hypertension, tachycardia)
ED while intoxicated: bradycardia and sedation → medetomidine withdrawal can emerge rapidly while still opioid-intoxicated
Admitted for other reasons: withdrawal develops over the course of hospital stay

treatment principles

The risk of under-treatment is far greater than the risk of over-sedation/hypopnoea. Early aggressive treatment may avoid ICU admission.

get IV access early — transition to parenteral meds promptly before vomiting starts
anticipate polysubstance use and mixed toxidromes (concurrent alcohol/benzodiazepine withdrawal, stimulant intoxication)
QTc prolongation is common (overlapping medications, electrolyte abnormalities from vomiting); TdP risk increases with bradycardia
for patients emerging from intoxication, monitor BP closely and start clonidine early before vomiting onset
resume community OAT (methadone, buprenorphine, slow-release oral morphine) at usual doses as soon as PO is tolerated

management

These recommendations are based on expert consensus (META:PHI 2026) and limited single-centre experience, not prospective trials.

Indications: elevated HR and BP above expected baseline (e.g. SBP > 160, HR > 120), nausea/vomiting, agitation/confusion.

alpha-2 agonist therapy

Clonidine (first-line):

hold if SBP < 100, HR < 60, O2 sat < 92%, RR < 10, POSS ≥ 3
loading: 0.3–0.6 mg PO q1h × 3 doses
maintenance: 0.3 mg PO q4h PRN for SBP > 120
can be given sublingually if vomiting, though absorption may be incomplete

Dexmedetomidine (escalation):

consider when: severe vomiting preventing PO, SBP > 200 or HR > 150, delirium/severe agitation
higher than typical doses often required
loading dose 1 mcg/kg IV over 10 min, then infusion; start at higher rates and titrate down

opioids

These doses assume significant opioid tolerance (e.g. regular unregulated fentanyl use). Monitor closely for respiratory depression, particularly with concurrent alpha-2 agonist therapy (clonidine, dexmedetomidine) which compounds sedation.

hydromorphone 4–8 mg SC/IV q15min PRN (up to 4 doses) for severe withdrawal
hydromorphone 8–16 mg PO q1h PRN if tolerating oral and no increased toxicity risk
double dose if no significant response (decrease ≥ 4 on COWS) as long as POSS < 3
resume community OAT as soon as PO tolerated; adjust based on last witnessed dose

COWS was designed for opioid withdrawal and may not adequately capture medetomidine-specific features (severity of hypertension, vomiting). Use clinical judgement alongside the score.

antiemetics

Ondansetron has TdP risk and has not been found helpful for medetomidine withdrawal in clinical experience (META:PHI consensus; no formal comparative data) — avoid it here.

If QTc permits:

olanzapine 10 mg PO/ODT (note: olanzapine itself has some QTc-prolonging potential — weigh against ondansetron risk in context)
haloperidol 2 mg IV/IM q4h PRN
dimenhydrinate — no TdP risk but may be less effective

benzodiazepines

diazepam 10–20 mg IV q2h PRN for agitation
midazolam 5–10 mg SC or lorazepam 2 mg SL/IM for agitation

inpatient OAT initiation

methadone or SROM within past 5 days: continue or adjust dose based on last witnessed dose
buprenorphine within past 5 days: resume full dose at once
not on OAT or > 5 missed doses:
- methadone: initiate at ≥ 40 mg (based on tolerance/toxicity risk) if QTc not prolonged — standard guidelines recommend 20–30 mg for uncertain tolerance; ≥ 40 mg reflects the high tolerance expected in this population but requires close monitoring, especially with concurrent alpha-2 agonist sedation
- SROM: initiate at 400 mg if QTc prolongation/TdP concern
- buprenorphine: microdosing/low-dose initiation to avoid precipitated withdrawal
titrate OAT to therapeutic dose (withdrawal controlled for 24h without PRNs)

discharge planning

involve social work, peer support, family (with permission); communicate with community provider
connect to WMS, RAAM clinic, and community services
clonidine taper: 0.3 mg TID × 3 days, then gradual taper over 2–3 weeks (7-day tapers may be too rapid)
counsel on risks of mixing clonidine with unregulated fentanyl
OAT prescription for up to 7 days or until next RAAM clinic
confirm follow-up; send discharge report to existing OAT provider

pharmacology note

Medetomidine is a racemic mixture of dexmedetomidine (active at alpha-2 receptors, used clinically as Precedex) and levomedetomidine. Atipamezole is the specific alpha-2 antagonist reversal agent used in veterinary medicine for medetomidine — not currently available for human use but a potential future therapeutic option.